AstraZeneca said Thursday it will seek full regulatory approval - as opposed to fast-track emergency use authorization - from the U.S. before the end of the year.
AstraZeneca said Thursday it will seek full regulatory approval - as opposed to fast-track emergency use authorization - from the U.S. before the end of the year.
Please to comment